Intracellular Trafficking of AAV5 Vectors

被引：1
|
作者：
Balakrishnan, Balaji [1 ,2 ]
Jayandharan, Giridhara R. [1 ,2 ]
机构：
[1] Christian Med Coll & Hosp, Dept Hematol, Vellore 632004, Tamil Nadu, India
[2] Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India
来源：
HUMAN GENE THERAPY METHODS | 2016年 / 27卷 / 02期
关键词：
ADENOASSOCIATED VIRUS; PATHWAY;
D O I：
10.1089/hgtb.2016.020
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The present study was designed to visualize the cellular trafficking of adeno-associated virus (AAV) vectors in general and AAV5 serotype vectors in particular. We fluorescently labeled AAV5 wild-type and a mutant (S652A) virus and studied their infection process by live cell imaging and confocal microscopy. Our data demonstrate considerable difference in the ability of these vectors to reach the nuclear compartment within the first 6 hr after infection.
引用
收藏
页码：47 / 48
页数：2
相关论文
共 50 条
  • [21] Defining In Vivo Biodistribution and Transduction Efficiency of AAV5 and AAV6 Vectors for In Utero Gene Therapy Using a Fetal Sheep Model
    Babatunde, Oluwaseun O.
    Rodriguez, Martin
    Wachtman, Sarah
    Perez, Jovanna
    Wilson, Jennifer
    Mohamed, Walaa
    Vaughan, William
    Atala, Anthony
    Doering, Christopher
    Spencer, H. Trent
    Porada, Christopher D.
    Almeida-Porada, M. Graca D.
    MOLECULAR THERAPY, 2024, 32 (04) : 275 - 276
  • [22] 新型重组AAV5/5载体及包装系统
    董小岩
    田文洪
    袁振华
    谭淑萍
    吴小兵
    生物工程学报, 2010, (05) : 679 - 686
  • [23] Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors
    Q Liu
    W Huang
    H Zhang
    Y Wang
    J Zhao
    A Song
    H Xie
    C Zhao
    D Gao
    Y Wang
    Gene Therapy, 2014, 21 : 732 - 738
  • [24] Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors
    Liu, Q.
    Huang, W.
    Zhang, H.
    Wang, Y.
    Zhao, J.
    Song, A.
    Xie, H.
    Zhao, C.
    Gao, D.
    Wang, Y.
    GENE THERAPY, 2014, 21 (08) : 732 - 738
  • [25] The Longitudinal Kinetics of AAV5 Vector Integration Profiles in Mice
    Ismail, Ashrafali Mohamed
    Witt, Evan
    Bouwman, Taren
    Clark, Wyatt
    Yates, Bridget
    Franco, Matteo
    Fong, Sylvia
    MOLECULAR THERAPY, 2023, 31 (04) : 35 - 35
  • [26] Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression
    Zhong, Li
    Li, Baozheng
    Jayandharan, Giridhararao
    Mah, Cathryn S.
    Govindasamy, Lakshmanan
    Agbandje-McKenna, Mavis
    Herzog, Roland W.
    Aken, Kirsten A. Weigel-Van
    Hobbs, Jacqueline A.
    Zolotukhin, Sergei
    Muzyczka, Nicholas
    Srivastava, Arun
    VIROLOGY, 2008, 381 (02) : 194 - 202
  • [27] Positive and negative effects of adenovirus type 5 helper functions on adeno-associated virus type 5 (AAV5) protein accumulation govern AAV5 virus production
    Nayak, Ramnath
    Pintel, David J.
    JOURNAL OF VIROLOGY, 2007, 81 (05) : 2205 - 2212
  • [28] Formulation development and feasibility of AAV5 as a lyophilized drug product
    Vargas, Stephanie K.
    Shari, Farrokh
    Nambayan, Reinard
    Moshashaee, Saeed
    Siahaan, Teruna J.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2025, 114 (02) : 1214 - 1223
  • [29] Sites in the AAV5 capsid tolerant to deletions and tandem duplications
    Hida, Kaoru
    Won, Sang Y.
    Di Pasquale, Giovanni
    Hanes, Justin
    Chiorini, John A.
    Ostermeier, Marc
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2010, 496 (01) : 1 - 8
  • [30] Strategies for Upstream Transfection Optimization in AAV5 Manufacturing Processes
    Mccoy, Taylor
    MOLECULAR THERAPY, 2022, 30 (04) : 189 - 189
12345